Emerging molecular targeted therapies in squamous cell carcinoma of the head and neck

Jill Gilbert, Athanassios Argiris

Research output: Contribution to journalArticle

2 Citations (Scopus)

Abstract

In recent years, several therapeutic advances have been made in squamous cell carcinoma of the head and neck (SCCHN). However, despite multimodality therapy, patients with locally advanced SCCHN continue to demonstrate suboptimal 5-year survival rates. The addition of novel, targeted agents to traditional therapies holds promise for clinical benefit. This review will focus on new agents that are promising and their potential role in the treatment of SCCHN.

Original languageEnglish (US)
Pages (from-to)611-619
Number of pages9
JournalClinical Advances in Hematology and Oncology
Volume4
Issue number8
StatePublished - Aug 2006
Externally publishedYes

Fingerprint

Molecular Targeted Therapy
Therapeutics
Survival Rate
Carcinoma, squamous cell of head and neck

Keywords

  • COX-2
  • EGFR
  • Head and neck cancer
  • Sorafenib
  • VEGF

ASJC Scopus subject areas

  • Oncology
  • Hematology

Cite this

Emerging molecular targeted therapies in squamous cell carcinoma of the head and neck. / Gilbert, Jill; Argiris, Athanassios.

In: Clinical Advances in Hematology and Oncology, Vol. 4, No. 8, 08.2006, p. 611-619.

Research output: Contribution to journalArticle

@article{519f7dd5b94e46b7af1d33d9fc13e9fd,
title = "Emerging molecular targeted therapies in squamous cell carcinoma of the head and neck",
abstract = "In recent years, several therapeutic advances have been made in squamous cell carcinoma of the head and neck (SCCHN). However, despite multimodality therapy, patients with locally advanced SCCHN continue to demonstrate suboptimal 5-year survival rates. The addition of novel, targeted agents to traditional therapies holds promise for clinical benefit. This review will focus on new agents that are promising and their potential role in the treatment of SCCHN.",
keywords = "COX-2, EGFR, Head and neck cancer, Sorafenib, VEGF",
author = "Jill Gilbert and Athanassios Argiris",
year = "2006",
month = "8",
language = "English (US)",
volume = "4",
pages = "611--619",
journal = "Clinical advances in hematology & oncology : H&O",
issn = "1543-0790",
publisher = "Millennium Medical Publishing, Inc.",
number = "8",

}

TY - JOUR

T1 - Emerging molecular targeted therapies in squamous cell carcinoma of the head and neck

AU - Gilbert, Jill

AU - Argiris, Athanassios

PY - 2006/8

Y1 - 2006/8

N2 - In recent years, several therapeutic advances have been made in squamous cell carcinoma of the head and neck (SCCHN). However, despite multimodality therapy, patients with locally advanced SCCHN continue to demonstrate suboptimal 5-year survival rates. The addition of novel, targeted agents to traditional therapies holds promise for clinical benefit. This review will focus on new agents that are promising and their potential role in the treatment of SCCHN.

AB - In recent years, several therapeutic advances have been made in squamous cell carcinoma of the head and neck (SCCHN). However, despite multimodality therapy, patients with locally advanced SCCHN continue to demonstrate suboptimal 5-year survival rates. The addition of novel, targeted agents to traditional therapies holds promise for clinical benefit. This review will focus on new agents that are promising and their potential role in the treatment of SCCHN.

KW - COX-2

KW - EGFR

KW - Head and neck cancer

KW - Sorafenib

KW - VEGF

UR - http://www.scopus.com/inward/record.url?scp=33748983981&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=33748983981&partnerID=8YFLogxK

M3 - Article

C2 - 17099619

AN - SCOPUS:33748983981

VL - 4

SP - 611

EP - 619

JO - Clinical advances in hematology & oncology : H&O

JF - Clinical advances in hematology & oncology : H&O

SN - 1543-0790

IS - 8

ER -